<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We had previously identified p53 mutations in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and therefore began a multiinstitutional study to determine their significance as a marker for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Ninety-eight patients from four institutions were studied </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-eight patients (37 men and 11 women, mean age 56.2 years) had <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with <z:mpath ids='MPATH_160'>metaplasia</z:mpath> or <z:mpath ids='MPATH_589'>dysplasia</z:mpath> but no evidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> at a mean follow-up of 2.2 years </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> was classified as <z:mpath ids='MPATH_160'>metaplasia</z:mpath> with no evidence of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in 32 patients, as low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in 13, and as high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in three </plain></SENT>
<SENT sid="4" pm="."><plain>The other 50 patients (46 men and four women, mean age 60.2 years) had <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> arising in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Tissues from <z:mpath ids='MPATH_458'>normal</z:mpath> stomach or esophagus, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> were obtained for <z:chebi fb="9" ids="16991">deoxyribonucleic acid</z:chebi> analysis by endoscopic biopsy from patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> or during operations on some patients with Barrett's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Exons 5 through 9 of the p53 gene were studied for mutations by single-strand conformational polymorphism analysis after polymerase chain reaction amplification </plain></SENT>
<SENT sid="7" pm="."><plain>Mutations detected by single-strand conformational polymorphism analysis were confirmed by <z:chebi fb="9" ids="16991">deoxyribonucleic acid</z:chebi> sequencing </plain></SENT>
<SENT sid="8" pm="."><plain>None of the tissue samples from patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> alone and no <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> had any p53 mutations, but one of the three patients with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and no evidence of invasive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> did have a p53 mutation </plain></SENT>
<SENT sid="9" pm="."><plain>Of the 50 patients with Barrett's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, however, 23 (46%) had p53 mutations in Barrett's epithelium, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, or both </plain></SENT>
<SENT sid="10" pm="."><plain>Twenty of these patients had p53 mutations in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> only (n = 16) or in both <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and Barrett's epithelium (n = 4), suggesting that the mutation plays a direct role in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Mutations in Barrett's epithelium were found in one patient in the group without <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and in seven patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (one with no <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, two with low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and five with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>) </plain></SENT>
<SENT sid="12" pm="."><plain>In three patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, mutations occurred only in Barrett's epithelium, suggesting that such mutations may also be a marker for genomic instability </plain></SENT>
<SENT sid="13" pm="."><plain>Mutations were predominantly found in exons 5, 7, and 8, and transitions from <z:chebi fb="1" ids="16235">guanine</z:chebi> to <z:chebi fb="1" ids="16708">adenine</z:chebi> were the most frequent changes </plain></SENT>
<SENT sid="14" pm="."><plain>Mutations of p53 are clearly involved in the pathogenesis of Barrett's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> for a subset of patients (46%), and the fact that we could detect mutations in premalignant Barrett's epithelium supports the hypothesis that p53 mutations may be a useful marker for patients at increased risk for development of <z:e sem="disease" ids="C0677898" disease_type="Neoplastic Process" abbrv="">invasive cancer</z:e> </plain></SENT>
</text></document>